TABLE 3.

Membrane fatty acid analysis of clinical isolates during log-phase growth

Fatty acid	% of total membrane content for indicated supplement and strain (avg ± SD)a
	BHI		Serumb		Bilec		C18:1 cis9d
	S613	R712	S613	R712	S613	R712	S613	R712
C12:0	0.6 ± 0.1	0.7 ± 0.1	0.3 ± 0.0	0.3 ± 0.0	0.2 ± 0.2	0.3 ± 0.3	0.9 ± 0.0	1.1 ± 0.0
C14:0	4.8 ± 0.1	3.7 ± 0.1	3.6 ± 0.1	2.4 ± 0.0	1.3 ± 0.1	1.6 ± 0.0	0.4 ± 0.1	0.6 ± 0.0
C16:1	7.9 ± 0.2	7.8 ± 0.2	5.0 ± 0.2	4.7 ± 0.0	1.1 ± 0.1	1.7 ± 0.1	1.0 ± 0.2	1.4 ± 0.1
C16:0	33.2 ± 0.2	28.2 ± 0.6	37.4 ± 0.6	36.6 ± 0.9	43.4 ± 0.7	43.0 ± 0.9	1.5 ± 0.2	1.9 ± 0.1
C17:0 2OH	4.8 ± 0.2	6.1 ± 0.1	0.5 ± 0.1	0.6 ± 0.1	ND	ND	ND	ND
C18:1 cis9	ND	ND	15.8 ± 0.8	18.6 ± 0.4	32.0 ± 1.6	38.1 ± 1.7	56.1 ± 3.4	57.8 ± 2.9
C18:1 cis11	44.1 ± 0.3	49.1 ± 0.2	7.5 ± 0.4	4.8 ± 0.2	3.1 ± 0.2	3.9 ± 0.2	0.5 ± 0.8	0.5 ± 0.8
C18:0	3.4 ± 0.2	3.4 ± 0.2	7.4 ± 0.1	7.3 ± 0.1	10.8 ± 1.7	6.2 ± 1.4	0.5 ± 0.0	0.4 ± 0.0
C20:0	ND	ND	0.1 ± 0.1	ND	2.6 ± 0.4	0.4 ± 0.4	38.6 ± 4.6	36.4 ± 3.6
C18:2	ND	ND	18.9 ± 1.2	21.3 ± 1.4	ND	ND	ND	ND
C20:4	ND	ND	1.1 ± 0.1	1.3 ± 0.1	0.4 ± 0.1	0.5 ± 0.1	ND	ND
Otherse	0.6 ± 1.0	0.7 ± 1.1	2.4 ± 1.4	2.3 ± 1.6	5.1 ± 0.7	4.4 ± 0.8	0.4 ± 0.1	ND
Saturated/unsaturated	0.8 ± 0.5	0.6 ± 0.8	1.0 ± 0.3	0.9 ± 0.5	1.6 ± 1.4	1.2 ± 1.1	0.7 ± 1.1	0.7 ± 1.0
C10-C17/C18-C20f	1.1 ± 0.01	0.9 ± 0.01	1.0 ± 0.1	0.9 ± 0.1	1.0 ± 0.3	1.0 ± 0.04	0.04 ± 0.0	0.05 ± 0.0

^aMembrane contents were determined by GC-FAME analysis by Microbial ID, Inc. Values represent averages and SD from three independent cultures. ND indicates that fatty acid was not detected.

^bPooled human serum was supplemented to a final concentration of 15%.

^cBovine bile was supplemented to a final concentration of 0.2%.

^dOleic acid was added to a final concentration of 20 μg/ml.

^eOthers indicates fatty acids that comprised <1% of the total membrane content.

^fTotal fatty acid length ratios including both saturated and unsaturated fatty acids.